INTEGRATED BIOPHARMA INC (INBP): Form 8-K filed 2026-11-13
- Accepted by EDGAR
- 2026-11-13 12:12 ET
- Event date
- 2026-11-13
- Accession no.
- 0001437749-26-036730
- Original filing
- SEC EDGAR filing index
AI summary of the filing text. It can contain mistakes; the original filing is authoritative.
Integrated BioPharma reports lower quarterly revenue and net loss
Integrated BioPharma reported revenue of $9.9 million for the quarter ended September 30, 2026, down approximately 22.0% from $12.7 million a year earlier. The Company reported a net loss of approximately $0.7 million, compared to net income of approximately $0.1 million in the prior-year quarter.
- Revenue was $9.9 million, down $2.8 million or approximately 22.0% from the quarter ended September 30, 2025.
- Operating loss was $1.0 million, compared to operating income of $0.2 million a year earlier.
- Net loss was approximately $0.7 million, compared to net income of approximately $0.1 million a year earlier.
- The two largest Contract Manufacturing Segment customers represented approximately 88% of total revenue.
earnings
Items reported
- Item 2.02: Results of Operations and Financial Condition
The company publicly announced results of operations or financial condition for a completed period, most often a quarterly earnings release. The release itself is usually attached as Exhibit 99.1. Information under Item 2.02 is generally "furnished" rather than "filed". - Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.
Documents
| Type | Description | Document |
|---|---|---|
| 8-K | FORM 8-K | inbp20261111_8k.htm |
| EX-99.1 | EXHIBIT 99.1 PRESS RELEASE NOVEMBER 13 2026 | ex_1043877.htm |
The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.